Urovant Sciences Ltd (UROV1)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Keith A. Katkin
Employees:
0
5151 CALIFORNIA AVENUE, SUITE 250, IRVINE, CA 92617
949-226-6029

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. The company is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom.

Data derived from most recent annual or quarterly report
Market Cap 531.753 Million Shares Outstanding32.743 Million Avg 30-day Volume 143.554 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3.47
Price to Revenue0.0 Debt to Equity0.0 EBITDA-126.705 Million
Price to Book Value0.0 Operating Margin0.0 Enterprise Value446.258 Million
Current Ratio2.128 EPS Growth0 Quick Ratio1.763
1 Yr BETA 0.6506 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-26.7132 Altman Z-Score-7.7194 Free Cash Flow to Firm 0
View SEC Filings from UROV1 instead.

View recent insider trading info

Urovant Sciences Ltd YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding UROV1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding UROV1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2021-03-31 by ROBINSON JAMES A. JR.
  • 4: filed on 2021-03-31 by HAAG-MOLKENTELLER CORNELIA
  • 4: filed on 2021-03-31 by LEGAULT PIERRE
  • 4: filed on 2021-03-31 by BANSAL AJAY
  • 4: filed on 2021-03-31 by HINDMAN JAMES M.
  • 4: filed on 2021-03-31 by KURSTJENS SEF
  • 4: filed on 2021-03-31 by JOHNSTON WALT
  • 4: filed on 2021-03-31 by SMITH BRYAN E.
  • 4: filed on 2021-03-31 by OCAMPO CHRISTINE
  • 4: filed on 2021-03-31 by POTTER MYRTLE S

    • Events (8k)

  • 8-K: filed on 2021-03-29:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
    Item 2.01: Completion of Acquisition or Disposition of Assets
  • 8-K: filed on 2021-03-24:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
  • 8-K: filed on 2021-02-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-02-11:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-02-09:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-12-23:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-11-17:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2020-11-13:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-10-07:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2020-09-23:
    Item 5.07: Submission of Matters to a Vote of Security Holders

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    POTTER MYRTLE S

    • Director
    		 No longer subject to file 2021-03-29 0

    BANSAL AJAY SEE REMARKS

    • Officer
    		 No longer subject to file 2021-03-29 0

    OCAMPO CHRISTINE PAO; CAO/UROVANT SCIENCES,INC.

    • Officer
    		 No longer subject to file 2021-03-29 0

    LEGAULT PIERRE

    • Director
    		 No longer subject to file 2021-03-29 0

    HINDMAN JAMES M.

    • Director
    		 No longer subject to file 2021-03-29 0

    ROBINSON JAMES A. JR. PEO;CEO/UROVANT SCIENCES, INC.

    • Officer
    • Director
    		 No longer subject to file 2021-03-29 0

    SMITH BRYAN E. GC/UROVANT SCIENCES, INC.

    • Officer
    		 No longer subject to file 2021-03-29 0

    KURSTJENS SEF

    • Director
    		 No longer subject to file 2021-03-29 0

    HAAG-MOLKENTELLER CORNELIA CMO/UROVANT SCIENCES, INC.

    • Officer
    		 No longer subject to file 2021-03-29 0

    JOHNSTON WALT SEE REMARKS

    • Officer
    		 No longer subject to file 2021-03-29 0

    KATKIN KEITH PEO;CEO/UROVANT SCIENCES, INC.

    • Officer
    • Director
    		 199,680 2020-02-19 0

    SUMITOMO CHEMICAL CO., LTD.

    DAINIPPON SUMITOMO PHARMA CO LTD

    SUMITOVANT BIOPHARMA LTD.

    • 10% Owner
    • SEE FOOTNOTE (1)SEE FOOTNOTE (1)
    		22,963,263 2020-02-19 0

    ROIVANT SCIENCES LTD.

    • 10% Owner
    		 No longer subject to file 2019-12-27 0

    NISHINAKA SHIGEYUKI

    • Director
    		 0 2019-12-27 0

    VIKING GLOBAL PERFORMANCE LLC

    VIKING GLOBAL EQUITIES LP

    VIKING GLOBAL EQUITIES II LP

    VGE III PORTFOLIO LTD.

    VIKING GLOBAL EQUITIES MASTER LTD.

    VIKING LONG FUND GP LLC

    VIKING LONG FUND MASTER LTD.

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    • 10% Owner
    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    		 No longer subject to file 2019-07-10 0

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    		 No longer subject to file 2019-07-10 0

    QVT ASSOCIATES GP LLC

    QVT FINANCIAL INVESTMENT CAYMAN LTD.

    • 10% Owner
    		 No longer subject to file 2019-07-10 0

    MACHADO PATRICK

    • FORMER 10% OWNER
    		 No longer subject to file 2019-07-10 0

    DEXXON HOLDINGS LTD.

    DEXCEL PHARMA TECHNOLOGIES LTD.

    OREN DAN

    • SEE REMARKSSEE REMARKSSEE REMARKS
    		 No longer subject to file 2019-07-10 0

    LO ANDREW

    • FORMER 10% OWNER
    		 No longer subject to file 2019-07-10 0

    SVF INVESTMENTS (UK) LTD

    SOFTBANK VISION FUND L.P.

    SVF GP (JERSEY) LTD

    SVF HOLDINGS (UK) LLP

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    		 No longer subject to file 2019-07-10 0

    TORTI FRANK

    • Director
    		 0 2019-07-09 0

    EBERSOLE NORI SVP;CHRO/UROVANT SCIENCES, INC

    • Officer
    		 0 2019-01-06 0

    MCFADDEN MICHAEL E. CCO/UROVANT SCIENCES, INC.

    • Officer
    		 0 2019-01-06 0

    VIKING GLOBAL EQUITIES MASTER LTD.

    • 10% Owner
    		 22,703,669 2019-01-01 0

    POTTER MYRTLE S

    POTTER MYRTLE S

    • Director
    		 0 2018-11-21 0

    VIKING GLOBAL PERFORMANCE LLC

    VIKING GLOBAL EQUITIES LP

    VIKING GLOBAL EQUITIES II LP

    VGE III PORTFOLIO LTD.

    VIKING LONG FUND GP LLC

    VIKING LONG FUND MASTER LTD.

    • 10% Owner
    		 22,703,669 2018-10-01 0

    QVT ASSOCIATES GP LLC

    QVT FUND V LP

    • 10% Owner
    		 22,703,669 2018-10-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    UROVANT SCIENCES LTD UROV 2021-03-29 19:15:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-29 18:45:02 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-29 18:15:02 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-29 17:45:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-29 17:15:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-29 16:45:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-29 16:15:02 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-29 15:45:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-29 15:15:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-29 14:45:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-29 14:15:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-29 13:45:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-29 13:15:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-29 12:45:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-26 22:15:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-26 21:45:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-26 21:15:03 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-26 20:45:02 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-26 20:15:04 UTC -3.1537 3.2237 400000
    UROVANT SCIENCES LTD UROV 2021-03-26 19:45:03 UTC -3.1537 3.2237 400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments